Fig. 3

Immune microenvironment, morphology, and molecular characteristic of the subset of UTROSCT. A, Immune microenvironment in benign and malignant UTROSCT. B, Predictive factor of stromal PD-L1 for disease-free survival (DFS) by Kappa Meier analysis. C, Morphology in benign and malignant UTROSCT. D, Predictive factor of mitotic activity for DFS by Kappa Meier analysis. E, Gene alteration of 5’ partners in benign and malignant UTROSCT. F, Gene alteration of 5’ partners for DFS by Kappa Meier analysis. G, Gene alteration of 3’ partners in benign and malignant UTROSCT. H, Predictive factor of gene alteration of 3’ partners for DFS by Kappa Meier analysis. *p<0.05, *Log-rank p<0.05